Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Luly Jay R., Chairman & CEO. Director active across 1 company, notably Enanta Pharmaceuticals INC. Aggregated, 22 disclosures have been logged. Breakdown: 1 buy · 4 sells. Total volume traded: €634k. History available since 15 September 2021. The latest transaction was disclosed on 12 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Luly Jay R.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4,516 shares@ US$59.056210.3% of flowCommon StockSEC:0001177648-21-000025:0
22 of 22 declarations
About Luly Jay R.
Luly Jay R. is Président-Directeur Général, and is listed as President and CEO at Enanta Pharmaceuticals INC (XNAS). Across 22 filings, the sampled filings run from 2021-09-17 to 2026-02-13, with 247034 EUR of buys and 386997 EUR of sells, and the most frequent transaction nature is Attribution.